Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
Clinical trial NCT05175235 · UNKNOWN
Trial details
- NCT number
- NCT05175235
- Sponsor
- National University Hospital, Singapore
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-19
- Primary completion
- 2023-05-31
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.